Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT

Maurizio Musso,R. Scalone,A. Crescimanno,V. Bonanno,V. Polizzi,F. Porretto,C. Bianchini,Tania Perrone

Published 2010 in Bone Marrow Transplantation

ABSTRACT

No abstract is available for this paper.

PUBLICATION RECORD

Publication year
2010
Venue
Bone Marrow Transplantation
Publication date
Unknown publication date
Fields of study
Medicine
Identifiers
DOI 10.1038/bmt.2009.114 PMID 19483762
External record
Open on Semantic Scholar
Source metadata
Semantic Scholar, PubMed

CITATION MAP

EXTRACTION MAP

CLAIMS

No claims are published for this paper.

CONCEPTS

No concepts are published for this paper.

REFERENCES

Palonosetron (Aloxi®) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy
2009cited by this paper
Palonosetron Exhibits Unique Molecular Interactions with the 5-HT3 Receptor
2008cited by this paper
Prevention of emesis from multiple-day and high-dose chemotherapy regimens.
2007cited by this paper
Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer
2007cited by this paper
Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study.
2006cited by this paper
Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment.
2006cited by this paper
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
2006cited by this paper
In vitro basis for schedule-dependent interaction between gemcitabine and topoisomerase-targeted drugs in the treatment of colorectal cancer.
2006cited by this paper
New antiemetic drugs.
2006cited by this paper
Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference.
2006cited by this paper
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.
2006cited by this paper
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
2005cited by this paper
Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer
2005cited by this paper
Ondansetron — a new safe and effective antiemetic in patients receiving high-dose melphalan
2004cited by this paper
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
2003cited by this paper
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
2003cited by this paper
Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting
2003cited by this paper
Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor antagonist
2003cited by this paper
A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis.
2003cited by this paper
Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support
2001cited by this paper
A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting
2000cited by this paper
Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy.
2000cited by this paper
Antiemetic therapy for high-dose chemotherapy with transplantation: report of a retrospective analysis of a 5-HT3 regimen and literature review
1999cited by this paper
Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation
1999cited by this paper
Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC).
1998cited by this paper
Ondansetron versus Methoclopramide, both combined with Dexamethasone, in the preventions of Cispltin induced delayed emesis.
1997cited by this paper
The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
1997cited by this paper
Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.
1997cited by this paper
Effect of postchemotherapy nausea and vomiting on health-related quality of life
1997cited by this paper
Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
1997cited by this paper
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
1997cited by this paper
Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer.
1995cited by this paper
The interaction of RS 25259‐197, a potent and selective antagonist, with 5‐HT3 receptors, in vitro
1995cited by this paper
Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy
1995cited by this paper
A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: Assessment of efficacy, safety and patient preference
1994cited by this paper
Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis.
1994cited by this paper
A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study Group.
1994cited by this paper
Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy.
1993cited by this paper
Phase III double‐blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple‐day cisplatin‐based chemotherapy
1992cited by this paper
Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.
1991cited by this paper

CITED BY